ILMN

Illumina Inc. (ILMN) | Rumor.io

Illumina

ILMN

Attention (50-day avg)0.02%

Attention rank (50-day avg)#313

Bullish sentiment (50-day avg)74%

Price to earnings ratio50.4

Market capitalization41.1B

Earnings per share5.37

Dividend yield (TTM)—

Revenue (annual)4.3B

Net income (annual)850M

Social

What share of all stock conversation is about ILMN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0.01% +0	0.03% +0.02	0.01% 0

Sep 25

Illumina's stock has reached a new all-time high, with a 158% increase since a bullish note on genomics last year.
The company's machines, consumables, and software enable drug companies to read and analyze genetic code for cancer, driving its growth.
Illumina's inclusion in the S&P 500 has contributed to its recent price increase, with a 7.2% jump on Thursday.

Generated by AI

Sentiment

Of the messages about ILMN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	84.96% -8.95	64.06% -31.35	92.15% +8.13
Bearish	—	15.04% +8.95	35.94% +31.35	7.85% -8.13

Bullish· Jul 30

Illumina's Q2 2026 revenue grew 9.5% YoY, driven by 8.1% organic growth ex-China, and the company raised its FY2026 guidance for revenue and EPS.
The company's non-GAAP operating margin was 22.5%, and it expects to maintain a non-GAAP operating margin of 23.4%-23.6% in FY2026.
Illumina's stock has reached a new 52-week high, and the company's CEO has raised its revenue and EPS guidance for FY2026, citing strong demand for its products in the clinical sequencing market.

Bearish· Nov 13

Genomics throughput is slowing, which may caution investors.
The slowdown in genomics throughput may impact Illumina's business.
Investors should be cautious about investing in Illumina due to the slowdown in genomics throughput.

Generated by AI

Topics

Of the messages about ILMN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	35.94%	85.29%	40.22%
Technical Analysis	—	17.19%	3.5%	4.23%
Macro	—	10.94%	5.03%	31.67%
Earnings	—	10.94%	1.01%	2.19%
Analysts	—	10.94%	4.97%	19.74%
Controversies	—	14.06%	0.19%	1.95%

Earnings· Jul 30

Illumina's Q2 2026 earnings report shows revenue of $1.16B, beating estimates by $30M, and non-GAAP EPS of $1.31, beating estimates by $0.08.
The company raised its FY26 guidance to $4.60-$4.64B in revenue and $5.30-$5.40 in non-GAAP EPS, both above prior ranges.
Illumina's Q2 2026 results were driven by 8.1% organic growth in the rest-of-world (excluding China) and a 9.5% increase in total revenue year-over-year.

Analysts· Aug 12

Illumina's price target has been cut by multiple analysts, with PTs ranging from $200 to $380.
Piper Sandler maintains an Overweight rating on Illumina, with a PT of $320, while Baird and Citigroup have lower ratings.
Analysts have attributed Illumina's recent miss and guidance cut to macro headwinds, with some maintaining a Neutral or Market Perform rating.

Announcements· Sep 4

Illumina, along with Bloom Energy and Everpure, is set to join the S&P 500 effective September 21, replacing Builders FirstSource.
The S&P 500 reshuffle will add Bloom Energy, Everpure, and Illumina to the index, while removing Molson Coors, The Trade Desk, and Builders FirstSource.
The inclusion of Illumina in the S&P 500 will boost the index's representation of the corresponding market value segment, as part of the quarterly rebalancing.

Controversies· Feb 4

Illumina ($ILMN) was added to China's unreliable entity list, along with PVH Corp ($PVH), due to "discriminatory measures" against Chinese companies.
The move is seen as a retaliation to US tariffs and part of the broader US-China trade tensions, with Illumina's market dominance and intellectual property disputes being key factors.
The blacklisting has led to a 5.1% decline in Illumina's stock price, with investors and analysts watching for potential consequences and future developments in the trade war.

Macro· Mar 19

ILMN's business model is focused on sequencing genes, not modifying them, which may have implications for profit streams.
The company's sequencing technology could enable genetic modification, but it does not directly manipulate genes.
ILMN's focus on genetic sequencing may create opportunities for those who can modify genes, potentially impacting the company's profits.

Technical Analysis· Jul 12

$ILMN has potential to bounce if it closes above $310, with a bullish signal below $300 indicating a bearish trend.
The stock's 200 SMA is at $317, and a retest of this level is possible, with the yearly RSI at 10 indicating a potential bounce.
Support levels for $ILMN include $300, with $270s as the next potential support zone if the current level fails to hold.

Generated by AI

Community

Of the messages about ILMN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	50.13%	46.5%	22.43%
Newcomers	100%	49.87%	53.5%	77.57%

Regulars· Sep 4

Illumina, Inc. has been added to the S&P 500, along with Bloom Energy and Everpure, effective September 21.
The company's stock price has been impacted by insider selling, with a director selling 158,138 shares worth $34.2M.
The addition of Illumina to the S&P 500 marks its second inclusion, having been previously removed in 2024, sparking questions about the company's stock performance.

Newcomers· Sep 24

The price of ILMN has surged, with the stock reaching $256, a gain of about 10% from the author's cost basis of $140.
ILMN's recent jump is attributed to a 52-week high breakout, driven by institutional buying, and a strong expansion volume, with key levels including a support/pivot zone at $231.
The stock's surge is also attributed to the FDA's focus on labeling rather than safety for Grail's Galleri multi-cancer blood test, which has led to a 34% increase in the stock price this week.

Generated by AI

News

Where Will Illumina Stock Be in 5 Years If Its AI Bet Pays Off? | The Motley Fool

Illumina's AI strategy is reshaping the investment case. See how sequencing, biological data, and drug-discovery partnerships could change what drives the company next.

10h agoThe Motley Fool

Illumina Stock Popped 7% to a 52-Week High. Here’s Where the Stock Goes From Here

Key Stats for Illumina StockCurrent Price: $273. 90Target Price (Mid): ~$412Street Target: ~$203Potential Total Return: ~50%Annualized IRR: ~10% / yearWhat Happened?Illumina (ILMN) closed at $273.

4d agoYahoo Finance

Illumina (ILMN) Tests Valuation As Russell Index Removal Forces A Fresh Look

Index removal puts Illumina in focus Illumina (ILMN) has been removed from the Russell Small Cap Value Index, an index reshuffle that can prompt mechanical selling and raise fresh questions about how the stock is being valued today. The index removal comes at a time when Illumina’s momentum is already strong, with a 1-day share price return of 7.25%, a 30-day share price return of 21.82% and a year-to-date share price return of 103.87%. These feed into a 1-year total shareholder return of...

5d agoYahoo Finance

Illumina stock hits 52-week high at 256.71 USD

5d agoInvesting.com

Illumina Stock Surges 94.9% YTD: What's Behind the Rally?

ILMN's 94.9% YTD rally reflects strong sequencing growth, clinical adoption and a raised 2026 outlook despite China headwinds.

5d agoYahoo! Finance Canada

Illumina Inc. stock outperforms competitors on strong trading day

7d agomarketwatch.com

Also Discussed

Investors talking about ILMN also mention

#	Name	Attention
1	Pacific Biosciences of California, Inc. Common StockPACB	0%0
2	10x Genomics Inc. Class A Common StockTXG	0%-0.02
3	Guardant Health Inc.GH	0%-0.11
4	NVTA - Invitae Corporation	——
5	Twist Bioscience CorporationTWST	0%-0.02
6	Beam Therapeutics IncBEAM	0.02%+0.02
7	CRISPR Therapeutics AGCRSP	0%0
8	ARK Genomic Revolution ETFARKG	0.25%+0.09
9	Editas Medicine, Inc.EDIT	0%+0
10	Thermo Fisher Scientific Inc.TMO	0%0

Illumina Inc.

Healthcare
Diagnostics & Research

Illumina Inc. is a global genomics and life sciences company that develops DNA sequencing and array-based technologies used to analyze genetic variation and biological function. Its products and systems support research, clinical testing, and applied markets across areas such as oncology, inherited and infectious diseases, reproductive health, and molecular diagnostics. Illumina also provides sequencing consumables, instruments, software, and support services that help laboratories generate, interpret, and manage genomic data. The company serves customers including academic institutions, genomic research centers, hospitals, pharmaceutical and biotechnology companies, and clinical laboratories. Headquartered in San Diego, California, and founded in 1998, Illumina plays a central role in making genomic analysis more widely accessible for research and healthcare applications.

Website

Location

5200 Illumina Way

San Diego, CA, 92122

United States

Social

What share of all stock conversation is about ILMN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0.01% +0	0.03% +0.02	0.01% 0

Sep 25

Illumina's stock has reached a new all-time high, with a 158% increase since a bullish note on genomics last year.
The company's machines, consumables, and software enable drug companies to read and analyze genetic code for cancer, driving its growth.
Illumina's inclusion in the S&P 500 has contributed to its recent price increase, with a 7.2% jump on Thursday.

Generated by AI

Sentiment

Of the messages about ILMN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	84.96% -8.95	64.06% -31.35	92.15% +8.13
Bearish	—	15.04% +8.95	35.94% +31.35	7.85% -8.13

Bullish· Jul 30

Illumina's Q2 2026 revenue grew 9.5% YoY, driven by 8.1% organic growth ex-China, and the company raised its FY2026 guidance for revenue and EPS.
The company's non-GAAP operating margin was 22.5%, and it expects to maintain a non-GAAP operating margin of 23.4%-23.6% in FY2026.
Illumina's stock has reached a new 52-week high, and the company's CEO has raised its revenue and EPS guidance for FY2026, citing strong demand for its products in the clinical sequencing market.

Bearish· Nov 13

Genomics throughput is slowing, which may caution investors.
The slowdown in genomics throughput may impact Illumina's business.
Investors should be cautious about investing in Illumina due to the slowdown in genomics throughput.

Generated by AI

Topics

Of the messages about ILMN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	35.94%	85.29%	40.22%
Technical Analysis	—	17.19%	3.5%	4.23%
Macro	—	10.94%	5.03%	31.67%
Earnings	—	10.94%	1.01%	2.19%
Analysts	—	10.94%	4.97%	19.74%
Controversies	—	14.06%	0.19%	1.95%

Earnings· Jul 30

Illumina's Q2 2026 earnings report shows revenue of $1.16B, beating estimates by $30M, and non-GAAP EPS of $1.31, beating estimates by $0.08.
The company raised its FY26 guidance to $4.60-$4.64B in revenue and $5.30-$5.40 in non-GAAP EPS, both above prior ranges.
Illumina's Q2 2026 results were driven by 8.1% organic growth in the rest-of-world (excluding China) and a 9.5% increase in total revenue year-over-year.

Analysts· Aug 12

Illumina's price target has been cut by multiple analysts, with PTs ranging from $200 to $380.
Piper Sandler maintains an Overweight rating on Illumina, with a PT of $320, while Baird and Citigroup have lower ratings.
Analysts have attributed Illumina's recent miss and guidance cut to macro headwinds, with some maintaining a Neutral or Market Perform rating.

Announcements· Sep 4

Illumina, along with Bloom Energy and Everpure, is set to join the S&P 500 effective September 21, replacing Builders FirstSource.
The S&P 500 reshuffle will add Bloom Energy, Everpure, and Illumina to the index, while removing Molson Coors, The Trade Desk, and Builders FirstSource.
The inclusion of Illumina in the S&P 500 will boost the index's representation of the corresponding market value segment, as part of the quarterly rebalancing.

Controversies· Feb 4

Illumina ($ILMN) was added to China's unreliable entity list, along with PVH Corp ($PVH), due to "discriminatory measures" against Chinese companies.
The move is seen as a retaliation to US tariffs and part of the broader US-China trade tensions, with Illumina's market dominance and intellectual property disputes being key factors.
The blacklisting has led to a 5.1% decline in Illumina's stock price, with investors and analysts watching for potential consequences and future developments in the trade war.

Macro· Mar 19

ILMN's business model is focused on sequencing genes, not modifying them, which may have implications for profit streams.
The company's sequencing technology could enable genetic modification, but it does not directly manipulate genes.
ILMN's focus on genetic sequencing may create opportunities for those who can modify genes, potentially impacting the company's profits.

Technical Analysis· Jul 12

$ILMN has potential to bounce if it closes above $310, with a bullish signal below $300 indicating a bearish trend.
The stock's 200 SMA is at $317, and a retest of this level is possible, with the yearly RSI at 10 indicating a potential bounce.
Support levels for $ILMN include $300, with $270s as the next potential support zone if the current level fails to hold.

Generated by AI

Community

Of the messages about ILMN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	50.13%	46.5%	22.43%
Newcomers	100%	49.87%	53.5%	77.57%

Regulars· Sep 4

Illumina, Inc. has been added to the S&P 500, along with Bloom Energy and Everpure, effective September 21.
The company's stock price has been impacted by insider selling, with a director selling 158,138 shares worth $34.2M.
The addition of Illumina to the S&P 500 marks its second inclusion, having been previously removed in 2024, sparking questions about the company's stock performance.

Newcomers· Sep 24

The price of ILMN has surged, with the stock reaching $256, a gain of about 10% from the author's cost basis of $140.
ILMN's recent jump is attributed to a 52-week high breakout, driven by institutional buying, and a strong expansion volume, with key levels including a support/pivot zone at $231.
The stock's surge is also attributed to the FDA's focus on labeling rather than safety for Grail's Galleri multi-cancer blood test, which has led to a 34% increase in the stock price this week.

Generated by AI

Illumina

Social

Sep 25

Bullish· Jul 30

Bearish· Nov 13

Earnings· Jul 30

Analysts· Aug 12

Announcements· Sep 4

Controversies· Feb 4

Macro· Mar 19

Technical Analysis· Jul 12

Regulars· Sep 4

Newcomers· Sep 24

Where Will Illumina Stock Be in 5 Years If Its AI Bet Pays Off? | The Motley Fool

Illumina Stock Popped 7% to a 52-Week High. Here’s Where the Stock Goes From Here

Illumina (ILMN) Tests Valuation As Russell Index Removal Forces A Fresh Look

Illumina stock hits 52-week high at 256.71 USD

Illumina Stock Surges 94.9% YTD: What's Behind the Rally?

Illumina Inc. stock outperforms competitors on strong trading day

Also Discussed

Illumina Inc.

Company Information

Location

Where Will Illumina Stock Be in 5 Years If Its AI Bet Pays Off? | The Motley Fool

Illumina Stock Popped 7% to a 52-Week High. Here’s Where the Stock Goes From Here

Illumina (ILMN) Tests Valuation As Russell Index Removal Forces A Fresh Look

Illumina stock hits 52-week high at 256.71 USD

Illumina Stock Surges 94.9% YTD: What's Behind the Rally?

Illumina Inc. stock outperforms competitors on strong trading day

Also Discussed

Social

Sep 25

Bullish· Jul 30

Bearish· Nov 13

Earnings· Jul 30

Analysts· Aug 12

Announcements· Sep 4

Controversies· Feb 4

Macro· Mar 19

Technical Analysis· Jul 12

Regulars· Sep 4

Newcomers· Sep 24